title: Optimizing the benefit to risk ratio of medical therapy of inflammatory bowel diseases.
abstract: Despite the progress in the treatment of Crohn's disease and ulcerative colitis, there is a dire need to improve the benefit to risk ration of clinical care for young patients with chronic diseases. Most of the effective therapies for IBD are immunosuppressants and carry a burden of toxicity. The present work has focused on improving the tolerance of medical therapy while preserving efficacy. We have demonstrated that a reduction of the i.v. cyclosporine dose to 2 mg/kg preserves clinical efficacy and opens the perspective to a reduced toxicity. This study has been internationally implemented in treatment guidelines. In a case of progressive multifocal leukencephalopathy, al lethal brain infection caused by JC virus, in a patient with Crohn's disease, we were able to link JC reactivation to a specific therapy inhibiting leukocyte trafficking. We took this observation further and attempted to develop a screening algorithm for early detection of JC viral replication. Although further studies are needed this may be a first step to safer treatment with anti integrin therapies. Finally we have demonstrated that patients with myenteric plexitis at the ileal resection margins at surgery for ileocolonic Crohn's disease have a higher endoscopic relapse rate throughout one year. Myenteric plexitis is the first histological marker guiding prophyalictic therapy in the postoperative setting.
authors.affiliation: Division of Gastroenterology, University of Leuven Hospitals, Department of Pathophysiology, KULeuven, Herestraat 49 - B 3000 Leuven.
authors.forename: G
authors.initials: G
authors.lastname: Van Assche
mesh_terms: D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use*; D004351:Drug Resistance; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000517:prevention & control; D012008:Recurrence; D012074:Remission Induction; D018570:Risk Assessment
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine